Cantor Fitzgerald Lifts Earnings Estimates for Immatics

Immatics N.V. (NASDAQ:IMTX) – Equities research analysts at Cantor Fitzgerald increased their FY2025 earnings per share estimates for Immatics in a research note issued to investors on Wednesday, November 19th. Cantor Fitzgerald analyst E. Schmidt now forecasts that the company will earn ($2.09) per share for the year, up from their prior estimate of ($2.15). The consensus estimate for Immatics’ current full-year earnings is ($0.72) per share. Cantor Fitzgerald also issued estimates for Immatics’ FY2026 earnings at ($1.76) EPS.

Several other brokerages have also recently issued reports on IMTX. Zacks Research raised shares of Immatics from a “strong sell” rating to a “hold” rating in a report on Monday, October 13th. Guggenheim lifted their price objective on Immatics from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Immatics in a research note on Wednesday, October 8th. Finally, Mizuho raised their target price on Immatics from $19.00 to $23.00 and gave the stock an “outperform” rating in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.33.

Immatics Trading Down 2.2%

Shares of NASDAQ IMTX opened at $10.10 on Friday. The company has a 50 day simple moving average of $9.15 and a two-hundred day simple moving average of $6.89. The stock has a market cap of $1.23 billion, a price-to-earnings ratio of -9.90 and a beta of 1.24. Immatics has a 12 month low of $3.30 and a 12 month high of $11.25.

Immatics (NASDAQ:IMTX) last released its earnings results on Monday, November 17th. The company reported ($0.49) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.01. Immatics had a negative return on equity of 24.16% and a negative net margin of 146.13%.The firm had revenue of $6.10 million during the quarter, compared to the consensus estimate of $12.53 million.

Institutional Investors Weigh In On Immatics

Several hedge funds have recently modified their holdings of the company. Bank of America Corp DE grew its position in shares of Immatics by 166.0% during the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock valued at $25,000 after acquiring an additional 2,231 shares during the period. Vontobel Holding Ltd. purchased a new position in Immatics during the second quarter worth approximately $59,000. Insigneo Advisory Services LLC acquired a new stake in Immatics in the third quarter valued at approximately $103,000. Engineers Gate Manager LP purchased a new stake in shares of Immatics in the second quarter valued at approximately $124,000. Finally, Fox Run Management L.L.C. acquired a new position in shares of Immatics during the 2nd quarter worth approximately $136,000. 64.41% of the stock is owned by hedge funds and other institutional investors.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.